MicroPort CardioFlow Medtech Corporation

SEHK:2160 주식 보고서

시가총액: HK$1.7b

MicroPort CardioFlow Medtech 미래 성장

Future 기준 확인 5/6

MicroPort CardioFlow Medtech is forecast to grow earnings and revenue by 102.9% and 23.5% per annum respectively. EPS is expected to grow by 103% per annum. Return on equity is forecast to be 1.4% in 3 years.

주요 정보

102.9%

수익 성장률

103.0%

EPS 성장률

Medical Equipment 수익 성장39.2%
매출 성장률23.5%
향후 자기자본 수익률1.4%
애널리스트 커버리지

Low

마지막 업데이트01 Oct 2024

최근 미래 성장 업데이트

MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 03
MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

Sep 27
MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Sep 27
After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Aug 07
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

Jun 19
Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

May 29
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

Apr 05
MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Feb 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Jan 18
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Oct 04
Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

May 31
Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

May 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

Apr 06
The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

Feb 08
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Oct 18
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Jun 30
We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

Apr 04
Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 03
MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Jan 21
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

Sep 05
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Jun 07
We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

May 03
Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

수익 및 매출 성장 예측

SEHK:2160 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026753998233
12/31/2025571-39-99-943
12/31/2024454-162-70-452
6/30/2024383-349-182-167N/A
3/31/2024360-410-210-187N/A
12/31/2023336-472-237-207N/A
9/30/2023319-491-250-216N/A
6/30/2023303-511-263-226N/A
3/31/2023277-483-247-204N/A
12/31/2022251-454-232-183N/A
9/30/2022245-345-270-191N/A
6/30/2022239-236-309-199N/A
3/31/2022220-209-290-180N/A
12/31/2021201-183-270-162N/A
9/30/2021176-265N/AN/AN/A
6/30/2021151-346N/AN/AN/A
3/31/2021128-372N/AN/AN/A
12/31/2020104-398-168-110N/A
12/31/201922-145-191-143N/A

애널리스트 미래 성장 예측

수입 대 저축률: 2160 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

수익 vs 시장: 2160 is forecast to become profitable over the next 3 years, which is considered above average market growth.

고성장 수익: 2160 is expected to become profitable in the next 3 years.

수익 대 시장: 2160's revenue (23.5% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

고성장 수익: 2160's revenue (23.5% per year) is forecast to grow faster than 20% per year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: 2160's Return on Equity is forecast to be low in 3 years time (1.4%).


성장 기업 발견